Recently Featured

Bayer scores landmark victory as Supreme Court overturns Roundup verdict

July 9, 2026
Bayer has achieved a significant legal victory as the U.S. Supreme Court has overturned a $1.25 million jury verdict in favor of a plaintiff who alleged that his exposure to the herbicide Roundup caused his non-Hodgkin lymphoma. This ruling is pivotal, as it directly impacts the ongoing litigation surrounding Roundup, where tens of thousands of…

InduPro Licenses Lonza’s Linker Payload Technologies and Bioconjugation Platforms

July 9, 2026
Lonza and InduPro have entered into a licensing agreement aimed at advancing innovative antibody-drug conjugate (ADC) therapies. Under this agreement, Lonza will provide InduPro with a non-exclusive, worldwide license to its proprietary GlycoConnect®, HydraSpace®, and linker-payload technologies. These technologies are expected to enhance the development of ADCs targeting up to two oncology antigens, facilitating the…

Fosun Pharma Expands Global Reach with Multi-Asset Alzheimer’s Strategy

July 9, 2026
Fosun Pharma is strategically diversifying its portfolio beyond oncology, focusing on Alzheimer’s disease as a key area for growth. In a recent interview with Fierce, co-president Xinli Wang, M.D., Ph.D., outlined how the company has rapidly expanded its capabilities through two significant deals aimed at enhancing its Alzheimer’s pipeline. This move is part of a…

FDA Accuses Pinnacle Biologics of Misleading Cancer Therapy Videos

July 9, 2026
The FDA has accused Pinnacle Biologics of producing promotional videos that hinder healthcare professionals’ ability to fully understand the indications for its photodynamic therapy cancer treatment. This scrutiny highlights the regulatory agency’s commitment to ensuring that marketing materials provide clear and comprehensive information essential for informed clinical decision-making. The implications of this finding are significant…

Ongoing Cases